Miltefosine for Mucosal Leishmaniasis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00373776 |
Recruitment Status
:
Completed
First Posted
: September 8, 2006
Last Update Posted
: September 8, 2006
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Leishmaniasis | Drug: miltefosine 2.5 mg/kg/day for 28 days | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 75 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Study Start Date : | April 2004 |
Study Completion Date : | May 2006 |

- Efficacy
- toxicity

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 12 Years and older (Child, Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Mucosal leishmaniasis
Exclusion Criteria:
- Abnormal liver function tests (LFT)
- Abnormal kidney function test
- Concomitant diseases

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00373776
Bolivia | |
Palos Blancos, Bolivia |
Principal Investigator: | Jaime soto, MD | CIBIC |
ClinicalTrials.gov Identifier: | NCT00373776 History of Changes |
Other Study ID Numbers: |
04--01 |
First Posted: | September 8, 2006 Key Record Dates |
Last Update Posted: | September 8, 2006 |
Last Verified: | September 2006 |
Keywords provided by AB Foundation:
mucosal leishmaniasis miltefosine |
Additional relevant MeSH terms:
Leishmaniasis Euglenozoa Infections Protozoan Infections Parasitic Diseases Skin Diseases, Parasitic Skin Diseases, Infectious Skin Diseases |
Miltefosine Antifungal Agents Anti-Infective Agents Antineoplastic Agents Antiprotozoal Agents Antiparasitic Agents |